ReviewFrontiers in oncology2021

Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies.

Hussein A Abbas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.